NCT05758415 - Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 2, 2023

Primary Completion Date

October 18, 2024

Study Completion Date

December 11, 2024

Conditions

Rotator Cuff Tendinopathy

Interventions

DRUG

Secukinumab

The participants will receive Secukinumab 300 mg s.c. at randomization (Baseline visit), Week 1, 2, 3, 4, 8, and 12

DRUG

Placebo

The participants will receive placebo s.c. at randomization (Baseline visit), Week 1, 2, 3, 4, 8, and 12

Trial Locations (24)

10400

Novartis Investigative Site, Bangkok

15006

Novartis Investigative Site, A Coruña

15705

Novartis Investigative Site, Santiago de Compostela

20157

Novartis Investigative Site, Milan

28034

Novartis Investigative Site, Madrid

32789

Conquest Research, Winter Park

46024

Novartis Investigative Site, Valencia

50200

Novartis Investigative Site, Chiang Mai

53100

Novartis Investigative Site, Siena

89119

LV Research, Las Vegas

91405

Medvin Clinical Research, Van Nuys

91942

Horizon Clinical Research, La Mesa

200040

Novartis Investigative Site, Shanghai

430022

Novartis Investigative Site, Wuhan

430033

Novartis Investigative Site, Wuhan

610041

Novartis Investigative Site, Chengdu

710004

Novartis Investigative Site, Xian

050051

Novartis Investigative Site, Shijiazhuang

31-141

Novartis Investigative Site, Krakow

85-100

Novartis Investigative Site, Swidnica

87-100

Novartis Investigative Site, Torun

00-874

Novartis Investigative Site, Warsaw

02-677

Novartis Investigative Site, Warsaw

08208

Novartis Investigative Site, Sabadell